Modulation of endothelial junctions as selective immunotherapy

调节内皮连接作为选择性免疫疗法

• 批准号: nhmrc : 1143230
• 负责人: Prof Jennifer Gamble
• 金额: $ 61.62万
• 依托单位: Australian National University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2018
• 资助国家: 澳大利亚
• 起止时间: 2018-01-01 至 2020-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/modulation-endothelial-junctions-selective-immunotherapy/1319908
• 关键词: Modulation; endothelial; junctions; selective; immunotherapy

We have developed a new drug (CD5-2) that targets the junctions of endothelial cells, the cell that lines all vessels. CD5-2 reduces oedema in diseases such as diabetic retinopathy and tumours. Thus it has potential as a new therapeutic in chronic inflammatory diseases where leaky blood vessels are central to the pathology. This grant will provide fundamental understanding of how CD5-2 induces such profound effects to alter the levels of oedema and alter inflammatory cell infiltrates in tissues.

我们已经开发出一种新药（CD5-2），靶向内皮细胞的连接处，内皮细胞排列在所有血管上。CD5-2可减少糖尿病视网膜病变和肿瘤等疾病的水肿。因此，它有潜力作为一种新的治疗慢性炎症性疾病，其中血管渗漏是核心的病理。这项资助将提供对CD5-2如何诱导改变水肿水平和改变组织中炎症细胞浸润的深刻影响的基本理解。